FGEN - FibroGen, Inc.
| Previous Close | 42.27 |
| Open | 42.44 |
| Bid | 40.00 x 900 |
| Ask | 45.00 x 1100 |
| Day's Range | 41.94 - 42.76 |
| 52 Week Range | 33.51 - 68.55 |
| Volume | 467,788 |
| Avg. Volume | 880,976 |
| Market Cap | 3.644B |
| Beta (3Y Monthly) | 2.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.07 |
| Earnings Date | Aug 5, 2019 - Aug 9, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.71 |
- Markit•9 days ago
See what the IHS Markit Score report has to say about FibroGen Inc.
FibroGen Inc NASDAQ/NGS:FGENView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for FGEN with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 11. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding FGEN are favorable, with net inflows of $2.57 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Insider Monkey•14 days ago
Here’s What Hedge Funds Think About FibroGen Inc (FGEN)
Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by nearly 9 percentage points since the end of the third quarter of 2018 as investors worried over the possible ramifications of rising interest rates and escalation of the trade war with China. The hedge funds and institutional investors we track typically invest more […]
- Simply Wall St.•17 days ago
Can We See Significant Institutional Ownership On The FibroGen, Inc. (NASDAQ:FGEN) Share Register?
Every investor in FibroGen, Inc. (NASDAQ:FGEN) should be aware of the most powerful shareholder groups. Generally...
- GlobeNewswire•17 days ago
FibroGen to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
SAN FRANCISCO, June 10, 2019 -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today.
- GlobeNewswire•22 days ago
FibroGen Appoints Suzanne Blaug to Board of Directors
“Suzanne Blaug joins the FibroGen Board of Directors at a key time for the company. “I am excited to join FibroGen's Board as the company prepares for critical next steps in the regulatory and commercial development of roxadustat for the treatment of anemia associated with CKD and in other important applications in the treatment of anemia.
- Zacks•last month
Implied Volatility Surging for FibroGen (FGEN) Stock Options
Investors need to pay close attention to FibroGen (FGEN) stock based on the movements in the options market lately.
- ACCESSWIRE•last month
FibroGen INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In FibroGen, Inc. To Contact The Firm
NEW YORK, NY / ACCESSWIRE / May 15, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of FGEN earnings conference call or presentation 9-May-19 9:00pm GMT
Q1 2019 FibroGen Inc Earnings Call
Motley Fool•last monthFibroGen Inc (FGEN) Q1 2019 Earnings Call Transcript
FGEN earnings call for the period ending March 31, 2019.
- Motley Fool•2 months ago
Here's Why FibroGen Fell as Much as 26.6% Today
The company reported confusing top-line results from an important batch of phase 3 safety studies. Were they successful?
- InvestorPlace•2 months ago
FibroGen News: Why FGEN Stock Is Plummeting Today
FibroGen news has FGEN stock down on Friday after releasing confusing results from a recent trial.Source: Shutterstock The report from FibroGen (NASDAQ:FGEN) has to do with its Roxadustat drug for treating kidney disease. The statements made by the company in this update weren't exactly clear. This includes "we believe there is no clinically meaningful difference in risk."These unclear statements from the company were able to give some investors doubts about the drug. However, it looks like the results are better than expected. It was just the wording in the FibroGen news release that was causing problems.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"There is confusion in the market currently, but this should become clear as more investors realize the data is positive and Roxa's risk/benefit is favorable, so we see the stock rebounding and moving back up over time," Jefferies analysts said in a statement obtained by FierceBiotech.The FibroGen news about Roxadustat comes in the company's earnings report for the first quarter of 2019. The poor wording and confusion was also dragging down an otherwise solid earnings report. * 7 Cloud Stocks to Buy on Overcast Days FibroGen reported losses per share of 53 cents on revenue of $23.86 million. Losses per share and revenue from the same time last year were 50 cents and $31.93 million. Wall Street was looking for the company to reported losses per share of 67 cents on revenue of $20.00 million.FGEN stock was down 24% as of noon Friday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Cloud Stocks to Buy on Overcast Days * 6 Stable Stocks Worth Buying for Protection * 5 Active Vanguard Funds That You Have to Own As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post FibroGen News: Why FGEN Stock Is Plummeting Today appeared first on InvestorPlace.
- Benzinga•2 months ago
The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 9) Alcon AG (NYSE: ALC ) ANI Pharmaceuticals Inc (NASDAQ: ...
- Zacks•2 months ago
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of 22.06% and 19.32%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
FibroGen: 1Q Earnings Snapshot
On a per-share basis, the San Francisco-based company said it had a loss of 53 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•2 months ago
FibroGen Reports First Quarter 2019 Financial Results
Positive topline results from pooled safety analyses of roxadustat Phase 3 global programCompleted one year of treatment in Phase 2 trial evaluating pamrevlumab in treatment of.
- GlobeNewswire•2 months ago
FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program
FibroGen, Inc. (FGEN) today announced topline results from the pooled safety analyses of the global Phase 3 program for roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI). The global pivotal Phase 3 trials were conducted by FibroGen and collaboration partners AstraZeneca and Astellas Pharma, Inc., for treatment of anemia in chronic kidney disease (CKD) patients across the non-dialysis-dependent (NDD), incident (newly initiated) dialysis, and dialysis-dependent (DD) CKD populations, enrolled from more than 50 countries.
- GlobeNewswire•2 months ago
FibroGen to Report First Quarter 2019 Financial Results
SAN FRANCISCO, May 06, 2019 -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019 after market.
- Zacks•2 months ago
Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss
Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.
- Zacks•2 months ago
Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•2 months ago
How Does Investing In FibroGen, Inc. (NASDAQ:FGEN) Impact The Volatility Of Your Portfolio?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you own shares in FibroGen, Inc. (NASDAQ:FGEN) then it's worth thinking about how it contributes t...
